Coherus Oncology (CHRS) Tax Provisions (2019 - 2023)

Coherus Oncology has disclosed Tax Provisions across 3 years of filings, most recently posting -$380000.0 for Q3 2023.

• Tax Provisions for Q3 2023 came in at -$380000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was -$380000.0 (changed N/A YoY), and the FY2023 annual result was -$380000.0, changed N/A from the prior year.
• Tax Provisions came in at -$380000.0 for Q3 2023 at Coherus Oncology, down from $1.1 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $2.0 million in Q4 2019 to a low of -$380000.0 in Q3 2023.
• The 3-year median for Tax Provisions is $873500.0 (2019), against an average of $751750.0.
• Peak annual rise in Tax Provisions reached 2437.25% in 2020, while the deepest fall reached 76.39% in 2020.
• Coherus Oncology's Tax Provisions stood at $2.0 million in 2019, then sank by 45.05% to $1.1 million in 2020, then slumped by 134.55% to -$380000.0 in 2023.
• The last three Tax Provisions figures came in at -$380000.0 (Q3 2023), $1.1 million (Q4 2020), and $200000.0 (Q3 2020), per Business Quant data.